Cargando…
Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy
Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory m...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253913/ https://www.ncbi.nlm.nih.gov/pubmed/37298672 http://dx.doi.org/10.3390/ijms24119721 |
_version_ | 1785056519486701568 |
---|---|
author | Lepre, Caterina Claudia Russo, Marina Trotta, Maria Consiglia Petrillo, Francesco D’Agostino, Fabiana Anna Gaudino, Gennaro D’Amico, Giovanbattista Campitiello, Maria Rosaria Crisci, Erminia Nicoletti, Maddalena Gesualdo, Carlo Simonelli, Francesca D’Amico, Michele Hermenean, Anca Rossi, Settimio |
author_facet | Lepre, Caterina Claudia Russo, Marina Trotta, Maria Consiglia Petrillo, Francesco D’Agostino, Fabiana Anna Gaudino, Gennaro D’Amico, Giovanbattista Campitiello, Maria Rosaria Crisci, Erminia Nicoletti, Maddalena Gesualdo, Carlo Simonelli, Francesca D’Amico, Michele Hermenean, Anca Rossi, Settimio |
author_sort | Lepre, Caterina Claudia |
collection | PubMed |
description | Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory molecular basis of DR. We focus on four important aspects of retinal neuroinflammation: (i) the exacerbation of endoplasmic reticulum (ER) stress; (ii) the activation of the NLRP3 inflammasome; (iii) the role of galectins; and (iv) the activation of purinergic 2X7 receptor (P2X7R). Moreover, this review proposes the selective inhibition of galectins and the P2X7R as a potential pharmacological approach to prevent the progression of DR. |
format | Online Article Text |
id | pubmed-10253913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102539132023-06-10 Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy Lepre, Caterina Claudia Russo, Marina Trotta, Maria Consiglia Petrillo, Francesco D’Agostino, Fabiana Anna Gaudino, Gennaro D’Amico, Giovanbattista Campitiello, Maria Rosaria Crisci, Erminia Nicoletti, Maddalena Gesualdo, Carlo Simonelli, Francesca D’Amico, Michele Hermenean, Anca Rossi, Settimio Int J Mol Sci Review Diabetic retinopathy (DR) is the most frequent microvascular retinal complication of diabetic patients, contributing to loss of vision. Recently, retinal neuroinflammation and neurodegeneration have emerged as key players in DR progression, and therefore, this review examines the neuroinflammatory molecular basis of DR. We focus on four important aspects of retinal neuroinflammation: (i) the exacerbation of endoplasmic reticulum (ER) stress; (ii) the activation of the NLRP3 inflammasome; (iii) the role of galectins; and (iv) the activation of purinergic 2X7 receptor (P2X7R). Moreover, this review proposes the selective inhibition of galectins and the P2X7R as a potential pharmacological approach to prevent the progression of DR. MDPI 2023-06-03 /pmc/articles/PMC10253913/ /pubmed/37298672 http://dx.doi.org/10.3390/ijms24119721 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lepre, Caterina Claudia Russo, Marina Trotta, Maria Consiglia Petrillo, Francesco D’Agostino, Fabiana Anna Gaudino, Gennaro D’Amico, Giovanbattista Campitiello, Maria Rosaria Crisci, Erminia Nicoletti, Maddalena Gesualdo, Carlo Simonelli, Francesca D’Amico, Michele Hermenean, Anca Rossi, Settimio Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title | Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title_full | Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title_fullStr | Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title_full_unstemmed | Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title_short | Inhibition of Galectins and the P2X7 Purinergic Receptor as a Therapeutic Approach in the Neurovascular Inflammation of Diabetic Retinopathy |
title_sort | inhibition of galectins and the p2x7 purinergic receptor as a therapeutic approach in the neurovascular inflammation of diabetic retinopathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253913/ https://www.ncbi.nlm.nih.gov/pubmed/37298672 http://dx.doi.org/10.3390/ijms24119721 |
work_keys_str_mv | AT leprecaterinaclaudia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT russomarina inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT trottamariaconsiglia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT petrillofrancesco inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT dagostinofabianaanna inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT gaudinogennaro inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT damicogiovanbattista inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT campitiellomariarosaria inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT criscierminia inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT nicolettimaddalena inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT gesualdocarlo inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT simonellifrancesca inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT damicomichele inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT hermeneananca inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy AT rossisettimio inhibitionofgalectinsandthep2x7purinergicreceptorasatherapeuticapproachintheneurovascularinflammationofdiabeticretinopathy |